Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Victrex (VCT)

Price 886.00p on 22-10-2024 at 16:30:01
Change 13.00p 1.49%
Buy 884.00p
Sell 883.00p
Buy / Sell VCT Shares
Last Trade: Buy 50,656.00 at 886.00p
Day's Volume: 125,270
Last Close: 886.00p
Open: 867.00p
ISIN: GB0009292243
Day's Range 864.00p - 886.00p
52wk Range: 864.00p - 1,577.00p
Market Capitalisation: £771m
VWAP: 878.6692p
Shares in Issue: 87m

Recent Trades History Victrex (VCT)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 50,656 886.00p Suspected BUY Trade
16:35:17 - 22-Oct-24
Buy* 2 884.00p SI Trade
16:29:46 - 22-Oct-24
Buy* 90 884.00p Automatic Execution
16:29:03 - 22-Oct-24
Buy* 8 884.00p Automatic Execution
16:24:13 - 22-Oct-24
Buy* 1 884.00p Automatic Execution
16:24:05 - 22-Oct-24
Buy* 40 884.00p Automatic Execution
16:24:03 - 22-Oct-24
Sell* 3 884.00p Automatic Execution
16:24:03 - 22-Oct-24
Sell* 22 884.00p Automatic Execution
16:24:03 - 22-Oct-24
Sell* 17 884.00p Automatic Execution
16:24:03 - 22-Oct-24
Sell* 5 884.00p Automatic Execution
16:24:03 - 22-Oct-24

Share Price History for Victrex

Time period:
to
Date Open High Low Close Volume

Share News for Victrex

LONDON BROKER RATINGS: Citigroup cuts Compass Group to 'neutral'

14th Oct 2024 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More

LONDON BRIEFING: Stocks called lower before US inflation expectations

14th Oct 2024 07:52

(Alliance News) - Stocks were called to open lower in London on Monday, after data from China showed that demand remains fragile in the world's number two economy. Read More

IN BRIEF: Victrex gets FDA go-ahead for knee replacement study

17th Sep 2024 16:17

Victrex PLC - Lancashire, England-based polymer solutions provider for automotive, aerospace, energy & industrial, electronics, and medical markets - Says US Food & Drug Administration has granted investigational device exemption approval for a staged study, in partnership with Maxx Orthopedics Inc, for Maxx's Freedom Total Knee System with Victrex's Invibio Peek-Optima Femoral Component. Study will be conducted in the US and compare the Peek-Optima component to a control group using traditional metal femoral components. Company notes that this study will build on the existing criminal trial in Belgium, Italy and India, "which has been progressing strongly since the first implant in 2021". It also expects a regulatory submission in India "imminently". Read More

LONDON BROKER RATINGS: Bunzl, Centrica and Whibread upped; Reckitt cut

29th Aug 2024 09:49

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More

LONDON BROKER RATINGS: Jefferies likes Victrex; Barclays ups Elementis

21st Aug 2024 09:26

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More

FTSE 100 Latest
Value8,306.54
Change-11.70

Login to your account

Forgot Password?

Not Registered